What considerations are there for the pharmacotherapeutic management of nonalcoholic steatohepatitis?

Expert Opin Pharmacother. 2021 Jul;22(10):1217-1220. doi: 10.1080/14656566.2021.1912014. Epub 2021 Apr 21.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Humans
  • Liver Cirrhosis
  • Non-alcoholic Fatty Liver Disease* / drug therapy
  • Risk Factors